查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2049527

神經退化性疾病治療市場報告：按適應症、藥物類型、給藥途徑、分銷管道和地區分類（2026-2034 年）

Neurodegenerative Disease Treatment Market Report by Indication, Drug Type, Route of Administration, Distribution Channel, and Region 2026-2034
出版日期: | 出版商: IMARC | 英文 143 Pages | 商品交期: 2-3個工作天內

價格

2025年，全球神經退化性疾病治療市場規模達818億美元。展望未來，IMARC Group預測，從2026年到2034年，該市場將以4.30%的複合年成長率成長，到2034年達到1,208億美元。

神經退化性疾病是指一系列腦部疾病，這些疾病會導致中樞神經系統（CNS）或周圍神經系統（PNS）中神經元的結構和功能進行性退化。目前，已有多種藥物可用於緩解患者的生理或心理症狀，並改善其生活品質。此外，研究人員正致力於開發分子診斷技術，特別是生物標記和成像光譜技術，以期早期發現和診斷神經退化性疾病，並阻止其進展。

過度飲酒導致腫瘤和中風發生率上升，加上人口老化加劇，是導致神經退化性疾病風險增加的主要因素之一。這進一步凸顯了分子診斷技術在神經退化性疾病早期診斷中的必要性，包括阿茲海默症、帕金森氏症、亨丁頓舞蹈症和肌萎縮性側索硬化症（ALS）。此外，研究人員正將神經病理學和分子生物學方法結合，以有效了解這些疾病的分類。他們也正在開發針對各種神經神經退化性疾病的微創篩檢測試。同時，許多國家的政府機構和非政府組織（NGO）正在支持各種健康教育宣傳活動，以提高公眾對神經退化性疾病風險因素的認知。其他因素，例如基礎設施的改善以及可支配收入的增加所帶來的醫療保健服務可近性的提高，預計也將推動未來幾年的市場成長。

本報告解答的主要問題

  • 全球神經退化性疾病治療市場隨著時間的推移發生了哪些變化，未來幾年我們預期會看到哪些趨勢？
  • 新冠疫情對全球神經退化性疾病治療市場產生了哪些影響？
  • 主要區域市場有哪些？
  • 按適應症分類的市場組成是什麼？
  • 依藥品類型分類，市場組成是怎樣的？
  • 依給藥途徑分類的市場區隔如何？
  • 按分銷管道分類的市場區隔如何？
  • 該產業價值鏈包含哪些不同階段？
  • 該行業的主要促進因素和挑戰是什麼？
  • 全球神經退化性疾病治療市場的結構是如何的？主要參與者有哪些？
  • 這個行業的競爭有多激烈？

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 二手資訊
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：全球神經退化性疾病治療市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依適應症分類

  • 多發性硬化症
  • 帕金森氏症
  • 阿茲海默症
  • 脊髓性肌肉萎縮症（SMA）
  • 亨丁頓舞蹈症
  • 其他

第7章 市場區隔：依藥物類型分類

  • N-甲基-D-天門冬胺酸受體拮抗劑
  • 選擇性血清素再回收抑制劑
  • 多巴胺抑制劑
  • 其他

第8章 市場區隔：依給藥途徑

  • 口服
  • 注射藥物
  • 其他

第9章 市場區隔：依分銷通路分類

  • 醫院藥房
  • 零售藥房
  • 其他

第10章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第11章 SWOT 分析

第12章：價值鏈分析

第13章：波特五力分析

第14章：價格分析

第15章 競爭格局

  • 市場結構
  • 大公司
  • 主要公司簡介
    • Biogen
    • Boehringer Ingelheim International GmbH
    • F. Hoffmann-La Roche AG
    • GlaxoSmithKline Plc
    • Merck & Co. Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi SA
    • Teva Pharmaceutical Industries Ltd.
    • UCB SA
Product Code: SR112026A3102

The global neurodegenerative disease treatment market size reached USD 81.8 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 120.8 Billion by 2034, exhibiting a growth rate (CAGR) of 4.30% during 2026-2034.

Neurodegenerative diseases refer to a group of brain disorders that lead to progressive degeneration of the structure and function of neurons in the central nervous system (CNS) or peripheral nervous system (PNS). Presently, several medications are available to reduce physical or mental symptoms and improve the quality of patients' life. Moreover, researchers are focusing on developing molecular diagnostics, especially biomarkers and imaging spectroscopy, to detect and diagnose neurodegenerative diseases at an early stage and prevent their progression.

The growing prevalence of tumors and stroke on account of excessive alcohol consumption, in confluence with the rising geriatric population, represents one of the major factors increasing the risk of developing neurodegenerative diseases. This is further escalating the need for molecular diagnostic techniques for early diagnosis of neurodegenerative disorders, including Alzheimer's disease , Parkinson's disease, Huntington's disease and amyotrophic lateral sclerosis. Apart from this, researchers are combining neuropathological methods with molecular biology techniques to understand the classification of these diseases effectively. They are also developing minimally invasive (MI) screening tests for different types of neurodegenerative diseases. Furthermore, governing agencies of numerous countries, along with non-governmental organizations (NGOs), are supporting various health education campaigns to generate awareness about the risk factors of neurodegenerative diseases. Other factors, such as increasing access to healthcare facilities on account of improving infrastructure and inflating disposable incomes, are anticipated to drive the growth of the market in the coming years.

KEY MARKET SEGMENTATION:

Breakup by Indication:

  • Multiple Sclerosis
  • Parkinson's Disease
  • Alzheimer's Disease
  • Spinal Muscular Atrophy (SMA)
  • Huntington's Disease
  • Others

Breakup by Drug Type:

  • N-methyl-D-aspartate Receptor Antagonists
  • Selective Serotonin Reuptake Inhibitors
  • Dopamine Inhibitors
  • Others

Breakup by Route of Administration:

  • Oral
  • Injectable
  • Others

Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

COMPETITIVE LANDSCAPE:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Biogen, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi S.A, Teva Pharmaceutical Industries Ltd. and UCB S.A.

KEY QUESTIONS ANSWERED IN THIS REPORT

  • How has the global neurodegenerative disease treatment market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global neurodegenerative disease treatment market?
  • What are the key regional markets?
  • What is the breakup of the market based on the indication?
  • What is the breakup of the market based on the drug type?
  • What is the breakup of the market based on the route of administration?
  • What is the breakup of the market based on the distribution channel?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global neurodegenerative disease treatment market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Neurodegenerative Disease Treatment Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Indication

  • 6.1 Multiple Sclerosis
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Parkinson's Disease
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Alzheimer's Disease
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Spinal Muscular Atrophy (SMA)
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Huntington's Disease
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Others
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast

7 Market Breakup by Drug Type

  • 7.1 N-methyl-D-aspartate Receptor Antagonists
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Selective Serotonin Reuptake Inhibitors
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Dopamine Inhibitors
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Route of Administration

  • 8.1 Oral
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Injectable
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Distribution Channel

  • 9.1 Hospital Pharmacies
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Retail Pharmacies
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Others
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Biogen
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Boehringer Ingelheim International GmbH
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 F. Hoffmann-La Roche AG
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
    • 15.3.4 GlaxoSmithKline Plc
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 SWOT Analysis
    • 15.3.5 Merck & Co. Inc.
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 Novartis AG
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 Pfizer Inc.
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Sanofi S.A
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Teva Pharmaceutical Industries Ltd.
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 UCB S.A
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Neurodegenerative Disease Treatment Market: Major Drivers and Challenges
  • Figure 2: Global: Neurodegenerative Disease Treatment Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 4: Global: Neurodegenerative Disease Treatment Market: Breakup by Indication (in %), 2025
  • Figure 5: Global: Neurodegenerative Disease Treatment Market: Breakup by Drug Type (in %), 2025
  • Figure 6: Global: Neurodegenerative Disease Treatment Market: Breakup by Route of Administration (in %), 2025
  • Figure 7: Global: Neurodegenerative Disease Treatment Market: Breakup by Distribution Channel (in %), 2025
  • Figure 8: Global: Neurodegenerative Disease Treatment Market: Breakup by Region (in %), 2025
  • Figure 9: Global: Neurodegenerative Disease Treatment (Multiple Sclerosis) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 10: Global: Neurodegenerative Disease Treatment (Multiple Sclerosis) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 11: Global: Neurodegenerative Disease Treatment (Parkinson's Disease) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 12: Global: Neurodegenerative Disease Treatment (Parkinson's Disease) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 13: Global: Neurodegenerative Disease Treatment (Alzheimer's Disease) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 14: Global: Neurodegenerative Disease Treatment (Alzheimer's Disease) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 15: Global: Neurodegenerative Disease Treatment (Spinal Muscular Atrophy- SMA) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 16: Global: Neurodegenerative Disease Treatment (Spinal Muscular Atrophy- SMA) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 17: Global: Neurodegenerative Disease Treatment (Huntington's Disease) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 18: Global: Neurodegenerative Disease Treatment (Huntington's Disease) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 19: Global: Neurodegenerative Disease Treatment (Others) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 20: Global: Neurodegenerative Disease Treatment (Others) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 21: Global: Neurodegenerative Disease Treatment (N-methyl-D-aspartate Receptor Antagonists) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 22: Global: Neurodegenerative Disease Treatment (N-methyl-D-aspartate Receptor Antagonists) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 23: Global: Neurodegenerative Disease Treatment (Selective Serotonin Reuptake Inhibitors) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 24: Global: Neurodegenerative Disease Treatment (Selective Serotonin Reuptake Inhibitors) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 25: Global: Neurodegenerative Disease Treatment (Dopamine Inhibitors) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 26: Global: Neurodegenerative Disease Treatment (Dopamine Inhibitors) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 27: Global: Neurodegenerative Disease Treatment (Others) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 28: Global: Neurodegenerative Disease Treatment (Others) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 29: Global: Neurodegenerative Disease Treatment (Oral) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 30: Global: Neurodegenerative Disease Treatment (Oral) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 31: Global: Neurodegenerative Disease Treatment (Injectable) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 32: Global: Neurodegenerative Disease Treatment (Injectable) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 33: Global: Neurodegenerative Disease Treatment (Others) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 34: Global: Neurodegenerative Disease Treatment (Others) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 35: Global: Neurodegenerative Disease Treatment (Hospital Pharmacies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 36: Global: Neurodegenerative Disease Treatment (Hospital Pharmacies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 37: Global: Neurodegenerative Disease Treatment (Retail Pharmacies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 38: Global: Neurodegenerative Disease Treatment (Retail Pharmacies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 39: Global: Neurodegenerative Disease Treatment (Others) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 40: Global: Neurodegenerative Disease Treatment (Others) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 41: North America: Neurodegenerative Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 42: North America: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 43: United States: Neurodegenerative Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 44: United States: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 45: Canada: Neurodegenerative Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 46: Canada: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 47: Asia-Pacific: Neurodegenerative Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 48: Asia-Pacific: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 49: China: Neurodegenerative Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 50: China: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 51: Japan: Neurodegenerative Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 52: Japan: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 53: India: Neurodegenerative Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 54: India: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 55: South Korea: Neurodegenerative Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 56: South Korea: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 57: Australia: Neurodegenerative Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 58: Australia: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 59: Indonesia: Neurodegenerative Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 60: Indonesia: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 61: Others: Neurodegenerative Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 62: Others: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 63: Europe: Neurodegenerative Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 64: Europe: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 65: Germany: Neurodegenerative Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 66: Germany: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 67: France: Neurodegenerative Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 68: France: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 69: United Kingdom: Neurodegenerative Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 70: United Kingdom: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 71: Italy: Neurodegenerative Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 72: Italy: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 73: Spain: Neurodegenerative Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 74: Spain: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 75: Russia: Neurodegenerative Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 76: Russia: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 77: Others: Neurodegenerative Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 78: Others: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 79: Latin America: Neurodegenerative Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 80: Latin America: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 81: Brazil: Neurodegenerative Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 82: Brazil: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 83: Mexico: Neurodegenerative Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 84: Mexico: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 85: Others: Neurodegenerative Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 86: Others: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 87: Middle East and Africa: Neurodegenerative Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 88: Middle East and Africa: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 89: Middle East and Africa: Neurodegenerative Disease Treatment Market: Breakup by Country (in %), 2025
  • Figure 90: Global: Neurodegenerative Disease Treatment Industry: SWOT Analysis
  • Figure 91: Global: Neurodegenerative Disease Treatment Industry: Value Chain Analysis
  • Figure 92: Global: Neurodegenerative Disease Treatment Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Neurodegenerative Disease Treatment Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Neurodegenerative Disease Treatment Market Forecast: Breakup by Indication (in Million USD), 2026-2034
  • Table 3: Global: Neurodegenerative Disease Treatment Market Forecast: Breakup by Drug Type (in Million USD), 2026-2034
  • Table 4: Global: Neurodegenerative Disease Treatment Market Forecast: Breakup by Route of Administration (in Million USD), 2026-2034
  • Table 5: Global: Neurodegenerative Disease Treatment Market Forecast: Breakup by Distribution Channel (in Million USD), 2026-2034
  • Table 6: Global: Neurodegenerative Disease Treatment Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 7: Global: Neurodegenerative Disease Treatment Market: Competitive Structure
  • Table 8: Global: Neurodegenerative Disease Treatment Market: Key Players